Search results for "SCHEDULE"

showing 10 items of 567 documents

Intermittent intramuscular clodronate therapy: a valuable option for older osteoporotic women

2005

Agingmedicine.medical_specialtyOsteoporosisTreatment outcomeMEDLINE.Injections IntramuscularDrug Administration Schedulelaw.inventionPhysical medicine and rehabilitationPharmacotherapyRandomized controlled triallawBone DensitymedicineHumansFemurVitamin DOsteoporosis PostmenopausalAgedPain MeasurementLumbar Vertebraecalcium clodronic acid vitamin DBone Density Conservation Agentsbusiness.industryGeneral Medicinemedicine.diseaseTreatment OutcomeBack PainPhysical therapyCalciumDrug Therapy CombinationFemaleGeriatrics and GerontologyClodronic Acidbusiness
researchProduct

Effect of adolescent exposure to WIN 55212-2 on the acquisition and reinstatement of MDMA-induced conditioned place preference.

2009

The present study employs a conditioned place preference procedure (CPP) to examine the effects of exposure to the cannabinoid agonist WIN 55212-2 (WIN) (0.1 and 0.5mg/kg) during adolescence on the reinforcing properties of +/-3,4-methylenedioxymetamphetamine hydrochloride (MDMA) (1.25 and 2.5mg/kg) in mice. On postnatal day (PD) 27, animals received a daily injection of the assigned treatment on 5 consecutive days, and three days later the place conditioning procedure was initiated (PD 35). The results suggest that pre-exposure to cannabinoids strengthens the properties of MDMA and favors reinstatement of the craving for the drug, which endorses the gateway hypothesis.

AgonistMaleReinforcement ScheduleTime Factorsmedicine.drug_classmedicine.medical_treatmentMorpholinesN-Methyl-34-methylenedioxyamphetamineSpatial BehaviorCravingPharmacologyNaphthalenesDevelopmental psychologyExtinction PsychologicalMiceRimonabantPiperidinesmedicineAnimalsDrug InteractionsCannabinoid Receptor AntagonistsBiological PsychiatryPharmacologyAnalysis of VarianceDose-Response Relationship DrugMDMAExtinction (psychology)Calcium Channel BlockersConditioned place preferenceBenzoxazinesAnimals NewbornHallucinogensCannabinoid receptor antagonistConditioning OperantPyrazolesCannabinoidmedicine.symptomRimonabantPsychologypsychological phenomena and processesmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats.

2002

Acute GABA transporter inhibition can induce anxiolytic-like behaviors. The present analysis addressed whether chronic treatment (23 days via drinking water) with a GABA transporter inhibitor affects rat behavior similar to acute treatment and interferes with additional benzodiazepine-receptor agonistic treatment. Seventy-one rats divided into seven groups were acutely treated with either vehicle, diazepam (2 mg/kg), zolpidem (0.05 mg/kg), tiagabine (19 mg/kg) or chronically with tiagabine with or without acute diazepam or zolpidem. Animals were behaviorally characterized in an elevated plus-maze. None of the treatments induced changes in the activity of the animals. Acute and chronic treat…

AgonistMalemedicine.medical_specialtyElevated plus mazeZolpidemGABA Plasma Membrane Transport ProteinsTime FactorsTiagabinemedicine.drug_classPyridinesNipecotic AcidsOrganic Anion TransportersPharmacologyAnxiolyticDrug Administration Schedulechemistry.chemical_compoundInternal medicinemedicineGABA transporterAnimalsNeurotransmitterMaze LearningTiagabineBiological PsychiatryDiazepambiologyBehavior Animalbusiness.industryMembrane ProteinsMembrane Transport ProteinsDrug SynergismRats Inbred StrainsRatsZolpidemPsychiatry and Mental healthEndocrinologyNeurologychemistryAnti-Anxiety Agentsbiology.proteinNeurology (clinical)businessCarrier ProteinsDiazepammedicine.drugJournal of neural transmission (Vienna, Austria : 1996)
researchProduct

Faldaprevir (BI 201335), BI 207127 and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results

2013

Background Faldaprevir (BI 201335) and deleobuvir (BI 207127) are direct-acting antiviral agents under development for the treatment of chronic HCV infection. This article describes the final results of the Phase Ib SOUND-C1 study that evaluated the interferon-free oral combination of faldaprevir, deleobuvir and ribavirin in 32 treatment-naive patients infected with HCV genotype 1. Methods Patients were randomized to receive deleobuvir 400 mg ( n=15) or 600 mg ( n=17) three times daily plus faldaprevir 120 mg once daily and weight-based ribavirin for 4 weeks. Interferon-free therapy was followed by response-guided faldaprevir plus pegylated interferon-α2a/ribavirin to week 24 or 48. Results…

Aminoisobutyric AcidsProline[SDV]Life Sciences [q-bio]610 Medicine & healthHepacivirusAntiviral AgentsDrug Administration SchedulePolyethylene GlycolsTherapy naive03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHcv genotype 1LeucineRibavirinMedicine2736 Pharmacology (medical)Pharmacology (medical)Oral therapy030304 developmental biologyPharmacology0303 health sciencesbusiness.industryRibavirinDeleobuvirInterferon-alpha2725 Infectious DiseasesHepatitis C ChronicViral LoadVirologyRecombinant Proteins3. Good healthThiazolesInfectious DiseasesTreatment Outcome10219 Clinic for Gastroenterology and Hepatology3004 PharmacologychemistryAcrylatesFaldaprevirQuinolines030211 gastroenterology & hepatologyBenzimidazolesDrug Therapy CombinationbusinessOligopeptides
researchProduct

Generation of monoclonal antibodies against human regulatory T cells.

2009

Abstract Natural CD4 + CD25 + Foxp3 + regulatory T cells (Tregs) control the activation of the immune system and therefore have become a major area of research in immunology. The generation of monoclonal antibodies against human Tregs offers the possibility to discover novel Treg-specific or Treg-associated surface markers and to identify targets for a therapeutic modulation of Tregs. Here we present a methodology optimized to efficiently induce and select mAb against human Tregs by repeated immunization of mice with Tregs from a single donor and a differential two-step flow cytometry-based hybridoma screening procedure.

Anticorps monoclonalmedicine.drug_classImmunologyReceptors Antigen T-Cellchemical and pharmacologic phenomenaCell SeparationBiologyMonoclonal antibodyT-Lymphocytes RegulatoryFlow cytometryEpitopesMiceImmune systemAntibody SpecificitymedicineImmunology and AllergyAnimalsHumansIL-2 receptorLeukapheresisImmunization ScheduleHybridomasmedicine.diagnostic_testInterleukin-2 Receptor alpha SubunitFOXP3Antibodies Monoclonalhemic and immune systemsForkhead Transcription FactorsT lymphocyteFlow CytometryImmunizationImmunologyFemaleEpitope MappingJournal of immunological methods
researchProduct

Effects of a brief pre‑admission telephone reminder on no‑show and dropout rates in substance use disorder treatment: a quasi‑experimental study

2022

Abstract Background Appointment no-show and early dropout from treatment represent major challenges in outpatient substance use disorder treatment, adversely affecting clinical outcomes and health care productivity. In this quasi-experimental study, we examined how a brief reminder intervention for new patients before their first appointment affected treatment participation and retention. No-shows (not attending any sessions) and dropouts (discontinuation of initiated treatment because of three consecutively missed appointments) were compared between a period with pre-admission telephone calls (intervention) and a period without such reminders (non-intervention). Methods Participants were a…

Appointments and SchedulesPsychiatry and Mental healthVDP::Medisinske Fag: 700::Helsefag: 800::Helsetjeneste- og helseadministrasjonsforskning: 806No-Show PatientsPatient DropoutsNorwaySubstance-Related DisordersReminder SystemsHealth PolicyHumansAmbulatory Care FacilitiesVDP::Samfunnsvitenskap: 200::Sosiologi: 220Telephone
researchProduct

Treatment challenges and investigational opportunities in autoimmune hepatitis.

2005

New drugs and advances in molecular biology afford opportunities to upgrade the treatment of autoimmune hepatitis. The aims of this study were to define treatment problems, identify possible solutions, and stimulate investigations to improve patient care. A clinical subcommittee of the International Autoimmune Hepatitis Group reviewed current management difficulties and proposed corrective actions. The assessment of new front-line and salvage therapies for adults and children were given top priority. Cyclosporine and mycophenolate mofetil were endorsed as drugs worthy of rigorous study in severe disease, and budesonide was endorsed for study as front-line therapy in mild disease. Diagnostic…

Autoimmune diseaseHepatitismedicine.medical_specialtyHepatologybusiness.industryAUTOIMMUNE/*THERAPYPsychological interventionGastroenterologyAutoimmune hepatitisHepatologymedicine.diseaseSurgeryTransplantationHEPATITISHepatitis AutoimmuneDosing schedulesInternal medicineEpidemiologymedicineHumansIntensive care medicinebusinessGASTROENTEROLOGY/*TRENDSHepatology (Baltimore, Md.)
researchProduct

Aviation Crew Recovery Experiences on Outstations

2016

Abstract ACMI flight crews spend considerable time away from home on outstations. This study suggests that this long term stay carries its own considerations in regards to rest recovery with practical implications for Fatigue Risk Management as prescribed by ICAO. Four recovery experiences, Work Detachment, Control, Relaxation and Mastery, are identified and correlated with 28 crew behaviours on base. The results indicate improvement considerations for airline management organizing a long term contract with ACMI crews, in particular to increase schedule stability to improve the crew member’s sense of Control.

Aviationhealth care facilities manpower and servicesControl (management)educationCrewAeronauticsjob resources0502 economics and businessrecovery experiencesPractical implicationsRisk managementFatigueMotor vehicles. Aeronautics. AstronauticsAviation crew; fatigue; job demands; job resources; recovery experiences050210 logistics & transportationbusiness.industry05 social sciencestechnology industry and agricultureaviation crewTL1-4050Term (time)Schedule (workplace)job demandsWork (electrical)fatiguePsychologybusiness050203 business & managementMarine engineering
researchProduct

Single-dose ebselen does not afford sustained neuroprotection to rats subjected to severe focal cerebral ischemia

2004

Oxygen free radicals have been involved in the pathophysiology of cerebral ischemia, especially after spontaneous or thrombolytic reperfusion. In this study with rats, we have combined a severe focal ischemic insult (2 h) and a prolonged reperfusion time (7 days) to assess the possible sustained neuroprotective effect of ebselen (10 or 100 mg/kg), a small, lipophilic organoselenium compound which mimics glutathione peroxidase. Parietal cortical perfusion was measured by laser-Doppler flowmetry, and focal cerebral ischemia was carried out by the intraluminal thread method. We have measured plasma selenium levels, brain reduced glutathione levels, as a marker of oxidative stress, and infarct …

AzolesMaleTime FactorsCentral nervous systemDrug Evaluation PreclinicalIschemiaAdministration OralIsoindolesPharmacologymedicine.disease_causeNeuroprotectionDrug Administration ScheduleBrain IschemiaSeleniumchemistry.chemical_compoundOrganoselenium CompoundsAnimalsMedicineRats WistarBrain ChemistryPharmacologychemistry.chemical_classificationbusiness.industryEbselenCerebral infarctionGlutathione peroxidaseBody WeightBrainInfarction Middle Cerebral ArteryGlutathionemedicine.diseaseGlutathioneRatsOxidative Stressmedicine.anatomical_structurechemistrySpainAnesthesiaReperfusionReactive Oxygen SpeciesbusinessOxidative stressEuropean Journal of Pharmacology
researchProduct

Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 study.

2018

Splenectomy in addition to immunotherapy with rituximab can provide quick and sometimes durable disease control in patients with splenic marginal zone lymphoma (SMZL). However, systemic chemotherapy is ultimately required in many cases. The BRISMA (Bendamustine-rituximab as first-line treatment of splenic marginal zone lymphoma)/IELSG (International Extranodal Lymphoma Study Group)36 trial is an open-label, single arm phase II study designed by the IELSG in cooperation with the Fondazione Italiana Linfomi and the lymphoma Study Association according to Simon's two-stage method. The primary endpoint was complete response rate. Fifty-six patients with SMZL diagnosis confirmed on central revis…

BendamustineAdultMalemedicine.medical_specialtyPhases of clinical researchNeutropeniaGastroenterologyDisease-Free SurvivalDrug Administration ScheduleSettore MED/15 - Malattie Del Sangue03 medical and health sciences0302 clinical medicineInternal medicinefirst-line therapyAntineoplastic Combined Chemotherapy ProtocolsMedicineBendamustine HydrochlorideHumansSplenic marginal zone lymphomabendamustineAgedbusiness.industrySplenic NeoplasmsHematologyLymphoma B-Cell Marginal ZoneMiddle Agedmedicine.diseaseLymphomaimmunochemotherapyRegimenTreatment Outcome030220 oncology & carcinogenesisbendamustine; first-line therapy; immunochemotherapy; rituximab; Splenic Marginal Zone Lymphoma; HematologySplenectomyRituximabFemaleSplenic Marginal Zone LymphomaNeoplasm Recurrence LocalbusinessRituximabFebrile neutropenia030215 immunologymedicine.drugBritish journal of haematology
researchProduct